Evidence map›Paper›PMID 37907623›Full record

ArticleClinical and experimental medicine2023

Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy.

Hai Cheng, Shengwei Ji, Jiaojiao Wang, Tian Hua, Zihan Chen, Jiaying Liu, Lingyan Shao, Xue Wang, Wei Chen, Wei Sang and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 1 country.

Hai Cheng *Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Shengwei Ji *Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Jiaojiao Wang *Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Tian Hua *Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Zihan ChenDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Jiaying LiuDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Lingyan ShaoDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Xue WangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Wei ChenDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Wei SangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Kunming QiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Zhenyu LiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Cai SunDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Ming ShiCancer Institute, Xuzhou Medical University, Xuzhou, 221002, China.
Jianlin QiaoJiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
Qingyun WuJiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
Lingyu ZengJiangsu Bone Marrow Stem Cell Institute, Xuzhou, 221002, China.
Xiaoming FeiDepartment of Hematology, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, China.
Hongming HuangDepartment of Hematology, The Affiliated Hospital of Nantong University, Nantong, 226000, China.
Weiying GuDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, 213000, China.
Kailin XuDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China. lihmd@163.com.
Junnian ZhengCancer Institute, Xuzhou Medical University, Xuzhou, 221002, China. jnzheng@xzhmu.edu.cn.
Jiang CaoDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China. zimu05067@163.com.
Xuzhou Medical College · CNAffiliated Hospital of Xuzhou Medical College · CNJiangsu University · CNNantong University · CNSoochow University · CN

Funding

the Key Research & Development Plan of Jiangsu Province BE2018634the Key Research & Development Plan of Jiangsu Province BE2020681the Key Research & Development Plan of Jiangsu Province BE2022711Xuzhou Medical leading talents Training program XWRCHT20210028
6 · The paper itself

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy exhibits remarkable efficacy against refractory or relapsed multiple myeloma (RRMM); however, the immune deficiency following CAR-Ts infusion has not been well studied. In this study, 126 patients who achieved remission post-CAR-Ts infusion were evaluated for cellular immunity. Following lymphodepletion (LD) chemotherapy, the absolute lymphocyte count (ALC) and absolute counts of lymphocyte subsets were significantly lower than baseline at D0. Grade ≥ 3 lymphopenia occurred in 99% of patients within the first 30 days, with most being resolved by 180 days. The median CD4

Indexed as

Multiple MyelomaReceptors, Chimeric AntigenCell- and Tissue-Based TherapyHumansImmunity, CellularImmunotherapy, AdoptiveReceptors, Chimeric AntigenB-cell maturation antigenCD19Cellular immune reconstitutionChimeric antigen receptor T cellsMultiple myeloma

Identifiers

PMID37907623
OpenAlexW4388038561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.